EP Patent

EP3763740A1 — Anti-kit antibodies and uses thereof

Assigned to Celldex Therapeutics Inc · Expires 2021-01-13 · 5y expired

What this patent protects

Provided herein is a monoclonal antibody or antigen-binding fragment thereof which immunospecifically binds to human KIT. Further provided herein is a conjugate or a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof. Further provided herein is…

USPTO Abstract

Provided herein is a monoclonal antibody or antigen-binding fragment thereof which immunospecifically binds to human KIT. Further provided herein is a conjugate or a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof. Further provided herein is a polynucleotide composition, an expression vector, a host cell, and a method for making such antibodies or antigen-binding fragments thereof. Also provided herein is the antibody or antigen-binding fragment thereof for use in a method for treating cancer, asthma, an inflammatory condition, or fibrosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP3763740A1
Jurisdiction
EP
Classification
—
Expires
2021-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Celldex Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.